Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRBI NASDAQ:ETON NASDAQ:IRWD NASDAQ:LXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRBIBR Biopharma$15.23+1.1%$14.89$12.15▼$67.01$177.97MN/A4,111 shs538 shsETONEton Pharmaceuticals$30.38+0.7%$22.19$13.09▼$32.31$825.17M0.82385,362 shs572,498 shsIRWDIronwood Pharmaceuticals$4.67+1.7%$3.67$0.53▼$5.78$748.44M0.291.74 million shs4.45 million shsLXRXLexicon Pharmaceuticals$1.65+3.1%$1.65$0.51▼$1.95$677.89M0.971.78 million shs1.59 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRBIBR Biopharma+3.18%+3.75%+2.28%+1,522,999,900.00%+1,522,999,900.00%ETONEton Pharmaceuticals+5.12%+25.75%+21.57%+105.97%+79.02%IRWDIronwood Pharmaceuticals+5.18%+11.19%+31.92%+4.01%+403.40%LXRXLexicon Pharmaceuticals+1.23%-0.60%+3.77%+29.92%+129.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRBIBR Biopharma$15.23+1.1%$14.89$12.15▼$67.01$177.97MN/A4,111 shs538 shsETONEton Pharmaceuticals$30.38+0.7%$22.19$13.09▼$32.31$825.17M0.82385,362 shs572,498 shsIRWDIronwood Pharmaceuticals$4.67+1.7%$3.67$0.53▼$5.78$748.44M0.291.74 million shs4.45 million shsLXRXLexicon Pharmaceuticals$1.65+3.1%$1.65$0.51▼$1.95$677.89M0.971.78 million shs1.59 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRBIBR Biopharma+3.18%+3.75%+2.28%+1,522,999,900.00%+1,522,999,900.00%ETONEton Pharmaceuticals+5.12%+25.75%+21.57%+105.97%+79.02%IRWDIronwood Pharmaceuticals+5.18%+11.19%+31.92%+4.01%+403.40%LXRXLexicon Pharmaceuticals+1.23%-0.60%+3.77%+29.92%+129.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRBIBR Biopharma 1.00SellN/AN/AETONEton Pharmaceuticals 2.40Hold$39.3329.47% UpsideIRWDIronwood Pharmaceuticals 2.43Hold$6.2333.48% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.15151.52% UpsideCurrent Analyst Ratings BreakdownLatest BRBI, IRWD, LXRX, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026IRWDIronwood Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/21/2026ETONEton Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/23/2026LXRXLexicon Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.003/20/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$37.00 ➝ $52.003/20/2026ETONEton Pharmaceuticals B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$26.00 ➝ $31.003/20/2026ETONEton Pharmaceuticals Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $35.003/19/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/12/2026LXRXLexicon Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.003/10/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.10 ➝ $2.303/5/2026LXRXLexicon Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $6.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRBIBR BiopharmaN/AN/AN/AN/AN/AN/AETONEton Pharmaceuticals$79.95M10.40$0.01 per share5,818.80$0.98 per share31.00IRWDIronwood Pharmaceuticals$296.15M2.57$0.26 per share17.83($1.61) per share-2.90LXRXLexicon Pharmaceuticals$49.80M14.04N/AN/A$0.30 per share5.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRBIBR BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AN/AETONEton Pharmaceuticals-$4.60M-$0.18N/A16.69N/A-5.75%-2.60%-0.66%5/12/2026 (Estimated)IRWDIronwood Pharmaceuticals$24.02M$0.1335.92N/AN/A8.11%-13.72%10.95%5/7/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.14N/AN/AN/A-101.08%-41.94%-22.03%5/7/2026 (Estimated)Latest BRBI, IRWD, LXRX, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ETONEton Pharmaceuticals$0.10N/AN/AN/A$22.31 millionN/A5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.24N/AN/AN/A$92.11 millionN/A5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04N/AN/AN/A$9.79 millionN/A3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 million3/5/2026Q4 2025LXRXLexicon Pharmaceuticals-$0.07-$0.04+$0.03-$0.04$3.14 million$5.49 million2/25/2026Q4 2025IRWDIronwood Pharmaceuticals$0.02-$0.01-$0.03-$0.01$86.10 million$47.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBRBIBR Biopharma$0.744.86%N/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRBIBR BiopharmaN/AN/AN/AETONEton Pharmaceuticals0.831.571.17IRWDIronwood PharmaceuticalsN/A1.131.13LXRXLexicon Pharmaceuticals0.464.884.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRBIBR BiopharmaN/AETONEton Pharmaceuticals27.86%IRWDIronwood PharmaceuticalsN/ALXRXLexicon Pharmaceuticals74.70%Insider OwnershipCompanyInsider OwnershipBRBIBR BiopharmaN/AETONEton Pharmaceuticals16.49%IRWDIronwood Pharmaceuticals12.70%LXRXLexicon Pharmaceuticals14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRBIBR BiopharmaN/A11.81 millionN/AN/AETONEton Pharmaceuticals2027.36 million22.85 millionOptionableIRWDIronwood Pharmaceuticals220163.06 million142.35 millionOptionableLXRXLexicon Pharmaceuticals140423.68 million364.37 millionOptionableBRBI, IRWD, LXRX, and ETON HeadlinesRecent News About These CompaniesLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules CapitalMay 4 at 4:05 PM | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200-Day Moving Average - Here's What HappenedMay 2, 2026 | marketbeat.comLexicon Pharmaceuticals (LXRX) to Release Earnings on ThursdayMay 2, 2026 | marketbeat.comLexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026April 30, 2026 | markets.businessinsider.comLexicon Shareholders Approve New Equity Plans, Capital IncreaseApril 30, 2026 | tipranks.comLexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026April 30, 2026 | globenewswire.comHow The Lexicon Pharmaceuticals (LXRX) Investment Story Is Shifting With Pilavapadin And LX9851April 27, 2026 | finance.yahoo.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200-Day Moving Average - What's Next?April 24, 2026 | marketbeat.comLexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin DataApril 23, 2026 | insidermonkey.comLexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingApril 17, 2026 | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 1-Year High - Here's WhyApril 16, 2026 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - Should You Buy?April 10, 2026 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Trading 6.3% Higher - Still a Buy?April 9, 2026 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average - What's Next?April 9, 2026 | marketbeat.comHow The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation AssumptionsApril 6, 2026 | finance.yahoo.comLexicon Pharmaceuticals (LXRX) price target increased by 15.07% to 3.43March 27, 2026 | msn.comLXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity DrugMarch 24, 2026 | zacks.comLexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & ExpoMarch 24, 2026 | globenewswire.comNovo Nordisk advances obesity pipeline with early-stage oral drug trial from Lexicon dealMarch 23, 2026 | msn.comLexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851March 23, 2026 | globenewswire.comHC Wainwright remains a buy on Lexicon Pharmaceuticals (LXRX)March 20, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBRBI, IRWD, LXRX, and ETON Company DescriptionsBR Biopharma NASDAQ:BRBI$15.23 +0.16 (+1.06%) As of 05/5/2026 03:52 PM Eastern This is a fair market value price provided by Massive. Learn more.BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.Eton Pharmaceuticals NASDAQ:ETON$30.38 +0.22 (+0.73%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$29.98 -0.40 (-1.32%) As of 05/5/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Ironwood Pharmaceuticals NASDAQ:IRWD$4.67 +0.08 (+1.74%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$4.70 +0.03 (+0.60%) As of 05/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Lexicon Pharmaceuticals NASDAQ:LXRX$1.65 +0.05 (+3.13%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.64 0.00 (-0.30%) As of 05/5/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
